Q-omics provides the consensus-scored LIMK2P1 profile across patient tissues and cancer cell-line models. LIMK2P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LIMK2P1 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, LIMK2P1 RNA expression shows 5,907 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRP, and STAD as cancer lineages where LIMK2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIMK2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIMK2P1 survival associations across molecular data types. LIMK2P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIMK2P1 RNA expression–survival associations across cancer types. High LIMK2P1 expression shows unfavorable associations in LUAD, BRCA, BLCA, COAD and STAD, but favorable associations in SARC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for LIMK2P1 RNA expression.
This table summarizes LIMK2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LIMK2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIMK2P1 shows lower tumor expression in KIRP, KIRC and THCA and higher tumor expression in HNSC. The KIRP box plot shows higher LIMK2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.030, t-test p = .012).
This table shows molecular features associated with LIMK2P1 in patient tissues and cancer cell lines. In patient samples, LIMK2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
